Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Advisor, aforementioned, Alexion, alia, ancillary, bifurcated, burden, Choi, circumvention, Cocrystal, collateral, conversion, correct, Counterclaim, customer, deficiency, degradation, denying, discrepancy, dominant, drafting, dual, earliest, EASL, Enanta, encapsidation, enjoin, ETV, exacerbate, Fargo, frame, front, GalNAc, Gastroenterology, glycolate, greatest, HBx, immaterial, impracticable, inflow, infrastructure, injunction, injunctive, Intellia, inter, Interbank, interdependent, intraday, kind, lender, LIBOR, MAA, manipulation, margin, mathematical, Modulator, outlook, overriding, overstatement, PegIFN, Perelman, pgRNA, poster, predominant, premium, presidential, procedure, purporting, rcDNA, reform, relief, renovate, repaid, repay, repeal, repealed, smaller, software, sophisticated, spreadsheet, steady, Sterilizer, supervision, Supplementary, Supreme, synergistic, titled, Topline, transition, Triple, Trump, uncoating, undelivered, understatement, unexercised, urged, urine, vitro, vivo, Warminster, withholding, wrongly
Removed:
AG, AlCana, Amyloidotic, awaiting, biomedical, body, bringing, choose, closed, conference, convert, dealing, declaration, demanded, determinable, discovered, element, emergency, employ, encapsulated, encouraging, filer, forfeiture, Germany, Hangzhou, Herrington, hiring, hosted, identifying, improving, initiate, irregular, Kowalski, labelling, LLP, manager, moved, moving, nil, North, payload, Polyneuropathy, prescribe, presenting, produced, provisional, reach, reaction, realizable, realize, relationship, safeguarded, San, submitted, Sutcliffe, systemic, translate, underwriter, USA, wide, workforce
Filing tables
Filing exhibits
- 10-K Annual report
- 10.62 Ex 10.62 Dod Termination
- 10.63 Exhibit 10.63 Neurovive Termination
- 10.64 Ex 10.64 Dicerna Termination
- 10.65 Ex 10.65 Cytos Termination
- 10.66 Ex 10.66 Bill Symonds Employ Amemd
- 10.67 Ex 10.67 Alexion License Agreement
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 31.1 Exhibit 31.1 10K CEO
- 31.2 Exhibit 31.2 10-K CFO
- 32.1 Exhibit 32.1 CEO Sox
- 32.2 Exhibit 32.2 CFO Sox
- Download Excel data file
- View Excel data file
Related press release
ABUS similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arbutus Biopharma Corporation (the “Company”) on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark J. Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company. |
Date: March 21, 2017
/s/ Mark J. Murray | |||
Name: | Mark J. Murray | ||
Title: | President and Chief Executive Officer |